Everything You Need To Know About Anivive’s LAVERDIA™, A Breakthrough Oral Tablet That Treats Canine Lymphoma
With new groundbreaking technology, Anivive discovered a new way for treating Lymphoma in dogs. Rather than chemotherapy, they developed what owners from the past have only dreamt of; a treatment that is taken 100% orally at home. Set to release this Spring 2021 in hopes to change the treatment of canine lymphoma, this has the potential to become the new normal. Here is everything you need to know about this exciting step forward in fighting canine lymphoma.
LAVERDIA Is FDA Approved
Anivive announced that their revolutionary drug was FDA approved on Jan. 21 2021. This was exciting for thousands of pet owners across the nation. Through trials and tribulations, Anivive has developed a treatment that is safe for our dogs to take by mouth and digest.
Through countless peer reviews and research trials, Anivive’s new drug has conditional approval while a complete trial of effectiveness under application number 141-526 continues. Conditional approval means that veterinarians have access to give LAVERDIA as the clinical trials continue for the full approval.
The New Oral Tablet Uses SINE Technology Specifically Designed to Treat T-cell and B-cell Lymphoma
This is a new approach to a therapeutic innovative treatment for canine lymphoma. It’s a huge breakthrough for veterinarians and dog owners everywhere. LAVERDIA-CA1 is the first small-molecule selective inhibitor of nuclear export that has been designed specifically for dogs. In Anivive’s release statement they explained the science of LAVERDIA;
“It is the first small-molecule selective inhibitor of nuclear export (SINE) drug specifically designed for veterinarian use. It employs a novel targeted mechanism of action where it targets and binds to Exportin-1 (XPO1) – a “transport” protein that proliferates in certain types of cancer. Excessive amounts of XPO1 export important tumor-suppressing proteins (TSPs) – necessary for fighting cancer – from the nuclei of cells, rendering them vulnerable to uncontrolled growth. With its targeted blocking of XPO1, LAVERDIA-CA1 allows for TSPs to be trapped inside the cell nucleus, triggering programmed cell death of lymphoma cells while sparing healthy cells” (Anivive Inc).
How Will Dogs Take LAVERDIA?
In Spring 2021 Anivive will release three different doses of LAVERDIA-CA1 (verdinexor tablets). Veterinarians will be able to prescribe the proper dose so dogs can receive treatment in their own homes. This is the first tablet treatment for Canine Lymphoma. It is simply given to your dog how you would any other oral medication. When prescribed your vet will discuss the best way to give LAVERDIA (Verdinexor) tablets.
LAVERDIA compared to other treatments:
Canine Lymphoma is a devastating disease, and inthe past, the treatment was also very difficult. During Anivive’s clinic trials and research, they discovered, “Nearly 80% of dog owners decline treatment” (Anivive Inc). Many pet owners found cost, access to a veterinary oncologist, and time-consuming treatments too much of a hurdle. Treatment was a long and difficult process, here’s a list of how LAVERDIA-CA is different:
- Taken from home
- Does not cause bone marrow suppression
- Easier to access
- Better quality of life for your dog!
Are There Any Side Effects?
Although LAVERDIA eliminates the normal side effects of typical treatments from the past. Anivive discovered that the most common side effects were of the following:
- Loss of Appetite
- Weight loss
This New Technology Was Discovered by Anivive, a Life Sciences and Biotechnology Company.
Anivive is a trailblazer in the pet pharma industry. Their business states that “Anivive discovers, develops, and commercializes specialty pet medicine.” They are a well respected and trusted company in the animal community. Anivive is on the forefront of drug development and implementation for canines. Their innovative approach makes treatments more affordable and available sooner.
Inc., Anivive Lifesciences. Anivive Announces FDA Conditional Approval of LAVERDIA™-CA1 (Verdinexor) – the First and Only Oral Tablet to Treat Lymphoma in Dogs, 21 Jan. 2021, www.prnewswire.com/news-releases/anivive-announces-fda-conditional-approval-of-laverdiatm-ca1-verdinexor–the-first-and-only-oral-tablet-to-treat-lymphoma-in-dogs-301212763.html?fbclid=IwAR3ZnuMRHPIl8U2i2QAX0Y7arRRQ6ypATl3-EWHi1CnDSWE1KRhx8N_DL5o.